← Eichor
Condition: Grade 1 Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Grade 1 Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07480941A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Phase 3 · 132 location(s) · National Cancer Institute (NCI) · NCT041664095G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260STARLITE for Unresectable High-Grade Gliomas
Phase 1 · 1 location(s) · University of Miami · NCT06428045A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refra
EARLY_Phase 1 · 1 location(s) · Children's National Research Institute · NCT07017816Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Phase 1/Phase 2 · 1 location(s) · Emory University · NCT04590664A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Phase 1/Phase 2 · 12 location(s) · Centre Leon Berard · NCT07243470ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519Study of Letrozole in Recurrent Gliomas
EARLY_Phase 1 · 1 location(s) · University of Cincinnati · NCT03122197A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · 127 location(s) · National Cancer Institute (NCI) · NCT05099003A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Pat
EARLY_Phase 1 · 1 location(s) · Nader Sanai · NCT07268053Preoperative Proton Irradiation for High-grade Brain Gliomas.
Phase 1 · 1 location(s) · National Medical Research Radiological Centre of the Ministr · NCT07710040A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · 70 location(s) · Fore Biotherapeutics · NCT05503797Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
Phase 1/Phase 2 · 8 location(s) · St. Justine's Hospital · NCT06666348SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Phase 1/Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT04923126Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Phase 1/Phase 2 · 3 location(s) · Plus Therapeutics · NCT01906385A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participant
EARLY_Phase 1 · 2 location(s) · St. Joseph's Hospital and Medical Center, Phoenix · NCT06072586ABY-029 Glioma Trial
Phase 1 · 1 location(s) · Dartmouth-Hitchcock Medical Center · NCT07063693Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phase 1/Phase 2 · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT07416188A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Phase 1 · 3 location(s) · Tetragon Biosciences Ltd · NCT07464925Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurre
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07544992Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Phase 1 · 1 location(s) · Nationwide Children's Hospital · NCT04254419A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in
Phase 1 · 1 location(s) · Mayo Clinic · NCT05789394Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
Phase 1 · 2 location(s) · Duke University · NCT06126744
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.